NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of purchasers of the securities of MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) resulting from allegations that MabVax may have issued materially misleading business information to the investing public.
On January 30, 2018, MabVax announced “that it received notice that the Securities and Exchange Commission (“SEC”) was conducting an investigation and examination pursuant to Section 8(e) of the Securities Act of 1933, as amended, relating to certain of the Company’s registration statements (and amendments thereto).” On this news, shares of MabVax fell sharply during intraday trading on January 30, 2018.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by MabVax investors. If you purchased shares of MabVax, please visit the firm’s website at http://www.rosenlegal.com/cases-1280.html or more information. You may also contact Phillip Kim or Daniel Sadeh of Rosen Law Firm toll free at 866-767-3653 or via email at firstname.lastname@example.org or email@example.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.